Expert Committee: FDA Should Allow Mitochondrial Replacement Trials Under Certain Conditions image

Regulatory Affairs, February 3, 2016
Zachary Brennan, quoting I. Glenn Cohen (Faculty Director)


Read the Full Article

From the article:

Glenn Cohen, faculty director of the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School, wrote on the center’s blog Wednesday: “The big headline is they have recommended FDA largely move toward allowing [MRT] to go forward under a regulatory pathway with restrictions, the most important of which is the transfer only of male embryos (to avoid germ-line issues)."

fda health law policy i. glenn cohen regulation reproductive rights